01.07.2022 07:00:14
|
DGAP-News: Newron extends Senior Management team and strengthens commitment to ESG
DGAP-News: Newron Pharmaceuticals S.p.A.
/ Key word(s): Personnel
Newron extends Senior Management team and Milan, Italy, July 1, 2022 Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is extending its Senior Management team through the appointment of Filippo Moriggia to the newly created position of Vice President of Operations, effective today. Filippo joined Newron in November 2016 as IT Director and became Director of Operations in January 2022. Furthermore, as part of a renewed commitment to Environment, Social and Governance (ESG) within its corporate strategy, Newron is undertaking a comprehensive assessment of key ESG topics that are material to the company and its stakeholders. Based on the findings of this assessment, Newron will subsequently develop relevant and measurable targets for its ESG activities and track progress to achieving these targets over time. To ensure appropriate oversight of this bolstered ESG commitment, Newrons Board of Directors has established an ESG Committee as per today. On an operational level, ESG implementation and reporting will be spearheaded by Filippo Moriggia. Stefan Weber, Newrons Chief Executive Officer, commented: We warmly welcome Filippo to the Senior Management team, and we are proud to have established for the first time an ESG committee on Board level, which underlines our renewed commitment to ESG. We look forward to conducting a thorough, company-wide assessment with our stakeholders to develop and define our ESG goals. Following which we will aim to publish our ESG strategy and targets by the end of 2022 and begin our annual ESG reporting in March 2023 with our next Annual Report.
For more information, please contact: Newron
01.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1387989 01.07.2022

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Newron Pharmaceuticals S.p.A.Az.mehr Nachrichten
26.02.25 |
Freundlicher Handel: Pluszeichen im SPI (finanzen.at) | |
26.02.25 |
SPI-Wert Newron PharmaceuticalsAz-Aktie: So viel Gewinn hätte eine Investition in Newron PharmaceuticalsAz von vor einem Jahr abgeworfen (finanzen.at) | |
19.02.25 |
SPI-Papier Newron PharmaceuticalsAz-Aktie: So viel Verlust hätte eine Investition in Newron PharmaceuticalsAz von vor 10 Jahren bedeutet (finanzen.at) | |
17.02.25 |
SPI aktuell: SPI notiert letztendlich im Plus (finanzen.at) | |
13.02.25 |
SIX-Handel: SPI legt am Donnerstagmittag zu (finanzen.at) | |
12.02.25 |
SPI-Wert Newron PharmaceuticalsAz-Aktie: So viel Gewinn hätte ein Investment in Newron PharmaceuticalsAz von vor 5 Jahren eingefahren (finanzen.at) | |
05.02.25 |
SPI-Papier Newron PharmaceuticalsAz-Aktie: So viel hätte eine Investition in Newron PharmaceuticalsAz von vor 3 Jahren abgeworfen (finanzen.at) | |
05.02.25 |
SPI aktuell: SPI beginnt Mittwochshandel mit Verlusten (finanzen.at) |
Analysen zu Newron Pharmaceuticals S.p.A.Az.mehr Analysen
Aktien in diesem Artikel
Newron Pharmaceuticals S.p.A.Az. | 9,57 | -1,54% |
|